S.V. BALALIN, T.G. EFREMOVA, V.N. POTAPOVA

The Volgograd branch of the S. Fyodorov Eye Microsurgery Federal State Institution, 80 Zemlyachki Str., Volgograd, Russian Federation, 400138 

 Balalin S.V. ― Doc. Med. Sc., Head of the Research Department, tel. (8442) 58-16-44, e-mail: mntk@isee.ru

Efremova T.G. ― Cand. Med. Sc., Head of the Department of Vitreoretinal Surgery, tel. (8442) 91-67-47, e-mail: mntk@isee.ru

Potapova V.N. ― Head of the Department of Laser Surgery, tel. (8442) 91-69-70, e-mail: mntk@isee.ru

We analyzed the results of surgical treatment of 42 patients (42 eyes) with neovascular glaucoma on the background of proliferative diabetic retinopathy. The patients from group 1 with neovascular glaucoma and the open angle of the anterior chamber, who underwent Lutsentis intravitreal injection, showed the reduction of intraocular pressure from 28.9±0.9 to 18.5±0.9 mmHg after drug treatment. Vision acuity increased from 0.23±0.07 to 0.44±0.9. The patients from group 2 (19 eyes) with neovascular glaucoma and the close angle of the anterior chamber, who first underwent trans-scleral cyclophotocoagulation (TSCPC), showed the mean reduction of intraocular pressure from 0.9±1.2 to 20.1±1.1 mmHg. During 1 year, all patients underwent the 2^nd stage of treatment, i.e., Lutsentis intravitreal injection. As a result, the intraocular pressure was reduced to 17.5±0.09 mmHg. Vision acuity increased from 0.18±0.10 to 0.25±0.09. Intravitreal administration of anti-VEGF drugs allows patients with NVG and the open angle of anterior chamber to remove the newly-formed vessels in the iris, in the anterior chamber angle, to lower intraocular pressure, to avoid complications, and, at the second stage, to perform laser surgery. In patients with NVG and closed anterior chamber angle of the eye, with glaucoma aching, the recommendation at the first stage is laser surgery, which allows to reduce intraocular pressure and to eliminate pain, and at the second stage intravitreal anti-VEGF drugs.

Key words: diabetes mellitus, neovascular glaucoma, intravitreal anti-VEGF drugs, trans-scleral cyclophotocoagulation.

REFERENCES

1. Vorob’eva I.V., Shcherbakova E.V. Glaucoma and diabetic retinopathy in patients with type 2 diabetes. Literature review. Oftal’mologiya, 2014, vol. 11, no. 3, pp. 4-12 (in Russ.).
2. Karaulovskaya E.A. Comprehensive treatment of neovascular glaucoma in patients with diabetes mellitus. Pole zreniya, 2012, no. 2, p. 11 (in Russ.).
3. Kushnir V.N., Rusu A.A., Kushnir V.V. Neovascular glaucoma — the problem of treatment and ways of their possible solutions. RMZh. Klinicheskaya oftal’mologiya, 2011, vol. 12, no. 4, pp. 129-130 (in Russ.).
4. Lipatov D.V., Kuz’min A.G., Bautina Yu.V. et al. The role of VEGF in the pathogenesis of neovascular glaucoma in patients with diabetes mellitus. RMZh. Klinicheskaya oftal’mologiya, 2011, vol. 12, no. 4, pp. 127-129 (in Russ.).
5. Nesterov A.P. Glaukoma. Moscow, 2008. 357 p.
6. Robustova O.V., Bessmertnyy A.M. Current concepts of etiology and pathogenesis of neovascular glaucoma. Glaukoma, 2003, no. 4, pp. 34-38 (in Russ.).
7. Wand M. Neovascular glaucoma. Ed.by R. Riteh, M.B. Shilds StLouis: C.V. Mosby Co 2002. Rr. 162-193.
8. Potapova V.N., Strel’nikov I.A., Koval’ G.A. Transskleral’naya tsiklofotokoagulyatsiya v lechenii pervichnoy i vtorichnoy glaukomy [Koval Trans-scleral cyclophotocoagulation in the treatment of primary and secondary glaucoma]. Sb. nauch. tr. i statey: Novye lazernye tekhnologii v oftal’mologii. Kaluga, 2002. P. 31.